Literature DB >> 9683600

Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease.

D P Germain1, J P Puech, C Caillaud, A Kahn, L Poenaru.   

Abstract

Gaucher disease (GD) is one of the most prevalent lysosomal storage disorders and one of the rare genetic diseases now accessible to therapy. Outside the Ashkenazi Jewish community, a high molecular diversity is observed, leaving approximately 30% of alleles undetected. Nevertheless, very few exhaustive methods have been developed for extensive gene screening of a large series of patients. Our approach for a complete search of mutations was the association of fluorescent chemical cleavage of mismatches with a universal strand-specific labeling system. The glucocerebrosidase (GBA) gene was scanned by use of a set of six amplicons, comprising 11 exons, all exon/intron boundaries, and the promoter region. By use of this screening strategy, the difficulties due to the existence of a highly homologous pseudogene were easily overcome, and both GD mutant alleles were identified in all 25 patients studied, thus attesting to a sensitivity that approaches 100%. A total of 18 different mutations and a new glucocerebrosidase haplotype were detected. The mutational spectrum included eight novel acid beta-glucosidase mutations: IVS2 G(+1)-->T, I119T, R170P, N188K, S237P, K303I, L324P, and A446P. These data further indicate the genetic heterogeneity of the lesions causing GD. Established genotype/phenotype correlations generally were confirmed, but notable disparities were disclosed in several cases, thus underlining the limitation in the prognostic value of genotyping. The observed influence of multifactorial control on this monogenic disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683600      PMCID: PMC1377310          DOI: 10.1086/301969

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  50 in total

Review 1.  Gaucher disease: a prototype for molecular medicine.

Authors:  G A Grabowski; H M Saal; R J Wenstrup; N W Barton
Journal:  Crit Rev Oncol Hematol       Date:  1996-05       Impact factor: 6.312

2.  Prenatal molecular diagnosis of Gaucher disease.

Authors:  A Zimran; D Elstein; A Abrahamov; W Kuhl; K H Brown; E Beutler
Journal:  Prenat Diagn       Date:  1995-12       Impact factor: 3.050

3.  Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease.

Authors:  N Tayebi; S Cushner; E Sidransky
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

4.  Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema.

Authors:  E Verpy; M Biasotto; M Brai; G Misiano; T Meo; M Tosi
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

5.  Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease.

Authors:  D Germain; M Biasotto; M Tosi; T Meo; A Kahn; L Poenaru
Journal:  Hum Genet       Date:  1996-12       Impact factor: 4.132

6.  Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA.

Authors:  J Sorge; C West; B Westwood; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  beta-Glucosidase assays in the diagnosis of Gaucher's disease.

Authors:  L B Daniels; R H Glew
Journal:  Clin Chem       Date:  1982-04       Impact factor: 8.327

8.  Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.

Authors:  H Cuppens; W Lin; M Jaspers; B Costes; H Teng; A Vankeerberghen; M Jorissen; G Droogmans; I Reynaert; M Goossens; B Nilius; J J Cassiman
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

9.  Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage.

Authors:  G Rowley; S Saad; F Giannelli; P M Green
Journal:  Genomics       Date:  1995-12-10       Impact factor: 5.736

10.  Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor.

Authors:  R Rozmahel; M Wilschanski; A Matin; S Plyte; M Oliver; W Auerbach; A Moore; J Forstner; P Durie; J Nadeau; C Bear; L C Tsui
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

View more
  7 in total

1.  Gaucher disease: variability in phenotype among siblings.

Authors:  D Amato; T Stachiw; J T R Clarke; G E Rivard
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

3.  The non-lysosomal β-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi.

Authors:  Heinz G Körschen; Yildiz Yildiz; Diana Nancy Raju; Sophie Schonauer; Wolfgang Bönigk; Vera Jansen; Elisabeth Kremmer; U Benjamin Kaupp; Dagmar Wachten
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 4.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

5.  Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease.

Authors:  Yildiz Yildiz; Per Hoffmann; Stefan Vom Dahl; Bernadette Breiden; Roger Sandhoff; Claus Niederau; Mia Horwitz; Stefan Karlsson; Mirella Filocamo; Deborah Elstein; Michael Beck; Konrad Sandhoff; Eugen Mengel; Maria C Gonzalez; Markus M Nöthen; Ellen Sidransky; Ari Zimran; Manuel Mattheisen
Journal:  Orphanet J Rare Dis       Date:  2013-09-26       Impact factor: 4.123

6.  A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.

Authors:  Ruth Abrams; Chanchala D Kaddi; Mengdi Tao; Randolph J Leiser; Giulia Simoni; Federico Reali; John Tolsma; Paul Jasper; Zachary van Rijn; Jing Li; Bradley Niesner; Jeffrey S Barrett; Luca Marchetti; M Judith Peterschmitt; Karim Azer; Susana Neves-Zaph
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-06-19

7.  The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects.

Authors:  Yoo-Mi Kim; Jin-Ho Choi; Gu-Hwan Kim; Young Bae Sohn; Jung Min Ko; Beom Hee Lee; Chong Kun Cheon; Han Hyuk Lim; Sun-Hee Heo; Han-Wook Yoo
Journal:  Orphanet J Rare Dis       Date:  2020-11-11       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.